Influenza chemotherapy: A review of the present state of art and of new drugs in development

Archives of Virology

Volumn 145, Issue 11, 2000, Pages 2233-2248

  Luscher Mattli M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENDONUCLEASE; HONG KONG; HOST CELL; INFLUENZA VACCINE; LETHAL MUTANT; REACTION MECHANISM; SIALIDASE INHIBITOR; TRANSCRIPTASE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VIRUS REPLICATION;

EID: 0034525788     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050070017     Document Type: Review

References (78)

1. Inhibition of influenza virus replication by phosphorothioate and liposomally encapsulated oligonucleotides
2. The neuraminidase of influenza virus
3. Update therapy of influenza and rhinovirus infections
4. Sulfated polysaccharides as potent inhibitors of HIV-induced syncythium formation: A new strategy towards AIDS chemotherapy
5. Human mucusprotease inhibitor in airway fluids is a potential defensive compound against infection with influenza and Sendai viruses
6. Inhibition of the fusion-inducing conformational change of influenza haemagglutinin by benzoquinones and hydroquinones
7. Flu virus invasion: Halfway there
8. Isolation of avian influenza A(H5N1) viruses from humans - Hong Kong, May-December 1997
9. Generation and in situ evaluation of libraries of poly(acrylic acid) presenting sialosides as side chains as polyvalent inhibitors of influenza-mediated haemagglutination
10. Biochemical studies on capped RNA primers indentify a class of oligonucleotide inhibitors of the influenza vius RNA polymerase
11. Differential effect of modified capped RNA substrates on influenza virus transcription
12. pH-dependent changes in photoaffinity labeling patterns of the HA1 influenza virus haemagglutinin by using an inhibitor of viral fusion
13. Preclinical development of low toxicity drugs: Focus on Zanamivir, an anti-influenza drug
14. The 1976 experience
15. H+ induced membrane insertion in influenza virus haemagglutinin involves the HA2 amino-terminal fusion peptide, but not the coiled-coil region
16. Membrane fusion promoted by increasing surface densities of paramyxovirus F and HN proteins: Comparison of fusion reactions mediated by simian virus 5F, human parainfluenza virus type 3F, and influenza virus HA
17. Dissection of a retrovirus envelope protein reveals structural similarity to influenza haemagglutinin
18. Influenza - Its impact and control
19. A novel mechanism for the acquisition of virulence by human influenza A virus
20. Requirement of vacuolar proton-ATPase activity during entry of influenza virus into cells
21. Surveillance for pandemic influenza
22. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors
23. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: In vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities
24. The influence of dextran sulfate on influenza A virus fusion with erythrocyte membranes
25. Structure-based identification of an inducer of the low-pH conformational change in influenza virus haemagglutinin: Irreversible inhibition of infectivity
26. Effects of protease inhibitors on replication of various myxoviruses
27. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins
28. In vitro and in vivo inhibition of ortho and paramyxovirus infections with a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion
29. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential
30. Novel negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity
31. A core trimer of the paramyxovirus fusion proteins: Parallels to influenza virus haemagglutinin and HIV-1 gp41
32. Vacuolar H+ ATPases. Targets for drug discovery?
33. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus and Sendai virus
34. Interspecies transmission of influenza C virus between humans and pigs
35. Evaluation of anti-influenza effects of camostat in mice, infected with non-adapted human influenza viruses
36. Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: Multivalency and steric stabilization of particulate biological systems
37. Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides
38. Polyanion inhibitors of human immunodeficiency virus and other viruses. 1. Polymerized anionic surfactants
39. Polyanion inhibitors of human immunodeficiency virus and other viruses. Part 2. Polymerized anionic surfactants derived from amino acids and dipeptides
40. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071
41. Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein
42. Dextran sulfate inhibits the fusion of influenza virus with model membranes and suppresses influenza virus replication in vivo
43. Characterization of a haemagglutinin-specific inhibitor of influenza A virus
44. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus
45. A comparative study of the effect of dextran sulfate on the fusion and the in vitro replication of influenza A and B, Semliki Forest, vesicular stomatitis, rabies, Sendai and mumps virus
46. Effective inhibitors of haemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition
47. Sulfonic acid polymers as a new class of human immonodeficiency virus inhibitors
48. Macrophage cytoplasmic vesicle pH gradients and vacuolar H+ ATPase activities relative to virus infection
49. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells
50. Unique sulfated polysaccharides from ascidians (Chordata, Tunicata) Brazil
51. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral haemagglutinin
52. Structure and function of the influenza virus M2 ion channel
53. Binding of influenza virus haemagglutinin to analogs of its cell-surface receptor, sialic acid: Analysis by proton nuclear magnetic resonance spectroscopy and X ray crystallography
54. Inhibition of influenza virus fusion by polyanionic proteins
55. Sulphated polymers are potent and selective inibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus and toga-arena-and retroviruses
56. Researchers seek new weapons against the flu
57. Current status of research and development for anti-influenza virus drugs-chemotherapy for influenza
58. Inhibition of influenza virus infections in mice by GS 4104, an orally effective influenza neuraminidase inhibitor
59. Inhibition of influenza virus haemagglutinin-mediated membrane fusion by a compound related to podocarpic acid
60. The HA2 subunit of influenza haemagglutinin inserts into the target membrane prior to fusion
61. Receptor binding and cell entry by influenza viruses
62. Amantadine selection of a mutant influenza virus containing an acid-stable haemagglutinin glycoprotein: Evidence for virus-specific regulation of the pH of glycoprotein transport vesicles
63. Influenza virus cleavage into HA1, HA2: No laughing matter
64. Initial genetic characterization of the 1918 "Spanish" influenza virus
65. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds
66. A novel antiviral agent which inhibits the endonuclease of influenza viruses
67. A potent anti-HIV agent in vitro having synergism with zidovidine
68. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution
69. A study of the active site of influenza virus sialidase: An approach to the rational design of novel anti-influenza drugs
70. Rational design of potent sialidase-based inhibitors of influenza virus replication
71. Zanamivir
72. Crystal structure of influenza virus haemagglutinin in complex with high-affinity receptor analogs
73. Influenza, an emerging disease
74. 2 protein in influenza virus uncoating: Specific reduction in the rate of membrane fusion between virus and liposomes by amantadine
75. Rimantadine: A clinical perspective
76. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs
77. Antiviral and therapeutic action of protease inhibitors in viral infections: Experimental and clinical observations